RiconPharma LLC
Home | Mirror Pharma | Login
Research Innovative Concepts
RiconPharma's Key Business Focus Strategies RiconPharma's Overview Presentation RiconPharma's Product Enhancement and Life Cycle Planning

About Us
Our History
Our Company
Our Team
Our Facility
Contact Us
  Our Team  
Raj Devalapalli
President & CEO - Co-Founder

Raj has an MS in Industrial Pharmacy and an MBA in Pharmaceutical Business with 20 years of proven experience in Pharmaceutical Product, Process, Technology and Manufacturing Development. Raj held key responsibility as Global Product and Process Technical Lead for a major pharmaceutical brand in Pfizer apart from leading several Technology Initiatives such as Continuous Processing, PAT, and Advanced Process Control. Raj held key positions in companies such as Pfizer, Warner Lambert, Becton Dickinson, and Penwest Pharmaceuticals (TIMERx Technologies).

Mukti Gande
CSO - Co-Founder

Mukti has an MS in Pharmaceutical Sciences with 18 + years of proven experience in Pharmaceutical Formulation R & D, API Sourcing, and Regulatory Submissions. Mukti was instrumental in the development and approval of several ANDA's and Paragraph IV's at CorePharma and Invamed (Sandoz). Mukti is also instrumental in submissions of NDA using 505(b)(2) regulatory pathway.
Dr. Praveen Reddy Billa
Managing Director - Co-Founder, RiconPharma India Private Limited

Praveen has a Ph.D in Pharmaceutics with 18 + years of proven experience in Pre-formulations, Analytical R & D, Formulation Development, and Regulatory Submissions. He held key positions in Pharmaceutical R & D at Wockhardt, Dr. Reddy's and Orchid. Most recently he was a Executive Senior Vice President, Pharmaceutical Research at Orchids Healthcare. He was instrumental in developing several ANDA's and challenged several Paragraph IV's. He has significant experience in Solid Oral Dosages, Topicals, Liquids, and Parenterals. He has several patents (US and WO) and publications.
  © 2017 RiconPharma LLC. All Rights Reserved. Powered By:   Team Tranquil Inc.